Jun 2026 (Q2 FY26) — Aug 13, 2026
Pershing Square Inc. Q2 FY26 — Strategic Fund Launches and PSUS Discount Management
Read the full callPershing Square earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 54.2 | +1.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -166.4 | −204.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -42.7 | −280.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
YTD: $24.2 on 29 Apr 2026 → $46.67. High $59.75 (6 Oct 2026), low $24.2 (29 Apr 2026).
Overview
Call summaries
Pershing Square Inc. Q2 FY26 — Strategic Fund Launches and PSUS Discount Management
Read the full callEvery analysed call
Financials
Net profit, year on year: −280% (quarter to jun 2026 against jun 2025).
| Line item | Mar 2025 | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 52 | 53 | 58 | 54 |
| Operating profit | 10 | 20 | 5 | -90 |
| Operating margin | 19.9% | 37.9% | 8.8% | −166.4% |
| Other income | 11 | 15 | -163 | 40 |
| Interest | 1 | 1 | 1 | 3 |
| Profit before tax | 22 | 35 | -158 | -50 |
| Tax rate | 8.3% | 5.5% | −0.5% | 18.6% |
| Net profit | 20 | 24 | -148 | -43 |
| EPS ($ per share) | — | 0.06 | — | -0.11 |
24 filings between Apr 28, 2026 and Aug 17, 2026.
Purchases
$19.02M
3 purchases by 1 insider
Sales
None
No insider sold shares.
Also filed: 8 other filings, 6 dispositions to the issuer, 2 gifts.
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| ACKMAN WILLIAM A | $19.02M | — | Apr 30, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 17, 2026 | ACKMAN WILLIAM A CEO & Chairman | Gift | 10,000,000 | $0 |
| Apr 30, 2026 | Coppel Calvo David Director | Award | 450,000 | — |
| Apr 30, 2026 | Coppel Calvo David Director | Award | 450,000 | — |
| Apr 30, 2026 | Lamotte Nicholas M Director | Award | 600,000 | — |
| Apr 30, 2026 | Lamotte Nicholas M Director | Other | 304,000 | — |
| Apr 30, 2026 | ACKMAN WILLIAM A CEO & Chairman | Other | 700,000 | — |
| Apr 30, 2026 | ACKMAN WILLIAM A CEO & Chairman | Purchase | 81,762 | $1.85M |
| Apr 30, 2026 | ACKMAN WILLIAM A CEO & Chairman | Purchase | 659,540 | $15.75M |
| Apr 30, 2026 | ACKMAN WILLIAM A CEO & Chairman | Purchase | 58,698 | $1.42M |
| Apr 30, 2026 | ACKMAN WILLIAM A CEO & Chairman | Other | 168,200 | — |
| Apr 30, 2026 | ACKMAN WILLIAM A CEO & Chairman | Other | 4,240 | — |
| Apr 30, 2026 | ACKMAN WILLIAM A CEO & Chairman | Award | 10,489 | — |
| Apr 30, 2026 | ACKMAN WILLIAM A CEO & Chairman | Disposition to issuer | 6,874,237 | $0 |
| Apr 30, 2026 | Coussin Halit CLO; CCO | Other | 40,000 | — |
| Apr 30, 2026 | ISRAEL RYAN Chief Investment Officer | Disposition to issuer | 667,614 | $0 |
| Apr 30, 2026 | ISRAEL RYAN Chief Investment Officer | Other | 100,000 | — |
| Apr 30, 2026 | Hakim Ben President | Disposition to issuer | 231,388 | $0 |
| Apr 30, 2026 | Hakim Ben President | Other | 20,000 | — |
| Apr 30, 2026 | Hakim Ben President | Award | 75,000 | — |
| Apr 30, 2026 | Coussin Halit CLO; CCO | Disposition to issuer | 197,771 | $0 |
| Apr 30, 2026 | Gonnella Michael Chief Financial Officer | Disposition to issuer | 192,426 | $0 |
| Apr 30, 2026 | Gonnella Michael Chief Financial Officer | Other | 20,000 | — |
| Apr 30, 2026 | Pershing Square Partner Group LLC Director | Disposition to issuer | 13,603,657 | $0 |
| Apr 28, 2026 | ACKMAN WILLIAM A CEO & Chairman | Gift | 300,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow PERSHING SQUARE INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading